AR108824A1 - DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY - Google Patents

DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY

Info

Publication number
AR108824A1
AR108824A1 ARP160103527A ARP160103527A AR108824A1 AR 108824 A1 AR108824 A1 AR 108824A1 AR P160103527 A ARP160103527 A AR P160103527A AR P160103527 A ARP160103527 A AR P160103527A AR 108824 A1 AR108824 A1 AR 108824A1
Authority
AR
Argentina
Prior art keywords
antibody derivatives
human
hiv
pharmaceutical composition
sample
Prior art date
Application number
ARP160103527A
Other languages
Spanish (es)
Inventor
Arbus Julin M Blanco
Sala Bonaventura Clotet
Molina Jorge Carrillo
Original Assignee
Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa filed Critical Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa
Publication of AR108824A1 publication Critical patent/AR108824A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Los derivados de anticuerpos de la presente solicitud se caracterizan por tener una mayor capacidad para (i) bloquear la entrada del virus de la inmunodeficiencia humana (VIH) a células huésped e (ii) inducir la activación de células asesinas naturales (NK) y otras células del sistema inmune. Varias formas de estos polipéptidos se describen y ejemplifican aquí. La presente también incluye las secuencias aisladas de ácidos nucleicos, vectores y células huésped que expresan dichos polipéptidos, al igual que sus aplicaciones terapéuticas y diagnósticas en salud humana. Reivindicación 1: Derivados de anticuerpos que comprenden del extremo N-terminal en dirección al extremo C-terminal: a) los dominios extracelulares D1 y D2 del receptor CD4 humano, b) el segmento Fc de una inmunoglobulina G humana, c) una fracción seleccionada del grupo que consiste de: i) un conector peptídico de secuencia (GGGGS)ₙ donde 1 £ n £ 10, ii) la secuencia del receptor CCR5 humano y iii) combinaciones de (i) y (ii), y d) un polipéptido derivado de gp41. Reivindicación 10: Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9 o una mezcla de ellos. Reivindicación 13: Derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9 o la composición farmacéutica de acuerdo a la reivindicación 10, para su uso en la prevención del VIH o el SIDA. Reivindicación 18: Un método para inducir la expresión de gp120 en una célula infectada de VIH que comprende contactar la célula infectada con los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5, las secuencias de nucleótidos de acuerdo a las reivindicaciones 6 ó 7, el vector de expresión de acuerdo a la reivindicación 8, la célula huésped de acuerdo a la reivindicación 9, la composición farmacéutica de acuerdo a la reivindicación 10, la combinación de acuerdo a las reivindicaciones 14 ó 15 o una mezcla de ellos. Reivindicación 19: Un método para detectar VIH en una muestra que comprende (a) contactar la muestra con los derivados de anticuerpos según cualesquiera de las reivindicaciones 1 a 5 y (b) determinar si los derivados de anticuerpos se acoplan específicamente a una molécula de la muestra.The antibody derivatives of the present application are characterized by having a greater ability to (i) block the entry of human immunodeficiency virus (HIV) into host cells and (ii) induce the activation of natural killer cells (NK) and others immune system cells. Several forms of these polypeptides are described and exemplified here. This also includes the isolated sequences of nucleic acids, vectors and host cells expressing said polypeptides, as well as their therapeutic and diagnostic applications in human health. Claim 1: Antibody derivatives comprising from the N-terminal end towards the C-terminal end: a) the extracellular domains D1 and D2 of the human CD4 receptor, b) the Fc segment of a human G immunoglobulin, c) a selected fraction from the group consisting of: i) a sequence peptide linker (GGGGS) ₙ where 1 £ n £ 10, ii) the sequence of the human CCR5 receptor and iii) combinations of (i) and (ii), and d) a derived polypeptide from gp41. Claim 10: A pharmaceutical composition comprising a therapeutically effective amount of the antibody derivatives according to any one of claims 1 to 5, the nucleotide sequences according to claims 6 or 7, the expression vector according to claim 8, the host cell according to claim 9 or a mixture thereof. Claim 13: Antibody derivatives according to any one of claims 1 to 5, the nucleotide sequences according to claims 6 or 7, the expression vector according to claim 8, the host cell according to claim 9 or the Pharmaceutical composition according to claim 10, for use in the prevention of HIV or AIDS. Claim 18: A method for inducing the expression of gp120 in an HIV infected cell comprising contacting the infected cell with antibody derivatives according to any of claims 1 to 5, the nucleotide sequences according to claims 6 or 7, the expression vector according to claim 8, the host cell according to claim 9, the pharmaceutical composition according to claim 10, the combination according to claims 14 or 15 or a mixture thereof. Claim 19: A method for detecting HIV in a sample comprising (a) contacting the sample with antibody derivatives according to any one of claims 1 to 5 and (b) determining whether antibody derivatives specifically attach to a molecule of the sample.

ARP160103527A 2015-11-21 2016-11-18 DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY AR108824A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201514948274A 2015-11-21 2015-11-21

Publications (1)

Publication Number Publication Date
AR108824A1 true AR108824A1 (en) 2018-10-03

Family

ID=58094460

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103527A AR108824A1 (en) 2015-11-21 2016-11-18 DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY

Country Status (8)

Country Link
US (1) US11866479B2 (en)
EP (2) EP3377524B1 (en)
JP (2) JP6991138B2 (en)
CN (1) CN108699131A (en)
AR (1) AR108824A1 (en)
ES (1) ES2910415T3 (en)
UY (1) UY36990A (en)
WO (1) WO2017085563A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018207023A2 (en) * 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
WO2020090747A1 (en) * 2018-10-29 2020-05-07 株式会社免疫生物研究所 Anti-hiv antibody and method for producing same
CN110846344A (en) * 2019-11-18 2020-02-28 山东省齐鲁细胞治疗工程技术有限公司 Chimeric antigen receptor T cell expressing IL-6R blocking antibody and targeting CD19, and preparation method and application thereof
WO2023205670A2 (en) * 2022-04-19 2023-10-26 Purdue Research Foundation Stable fc fragments, conjugates, compositions, and methods of use
CN116554356B (en) * 2023-05-16 2024-01-23 武汉大学 Fusion protein of hyper IL-15, sCD4 and Fc and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
EP1021548A1 (en) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20100249022A1 (en) * 2007-05-18 2010-09-30 University Of Massachusetts Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
AU2011248279A1 (en) * 2010-05-03 2012-11-01 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV
US20110305670A1 (en) * 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection

Also Published As

Publication number Publication date
US20210238252A1 (en) 2021-08-05
EP3377524A1 (en) 2018-09-26
EP3377524B1 (en) 2022-01-26
UY36990A (en) 2017-11-30
JP2022008978A (en) 2022-01-14
CN108699131A (en) 2018-10-23
EP4059956A1 (en) 2022-09-21
US11866479B2 (en) 2024-01-09
JP2019521639A (en) 2019-08-08
ES2910415T3 (en) 2022-05-12
WO2017085563A1 (en) 2017-05-26
JP6991138B2 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
AR108824A1 (en) DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY
Freyn et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
PE20191648A1 (en) NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USE THEM
AR095432A1 (en) PROTEINS OF UNION TO ANTIGEN
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PE20190418A1 (en) ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES
Mangino et al. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2
PE20190911A1 (en) ANTI-LAG-3 COMPOSITIONS AND ANTIBODIES
CL2013003634A1 (en) Complex comprising a fusion protein comprising, a viral peptide, linker peptide, beta 2 microglobulin, linker peptide, extracellular domains alpha 1, 2 and 3 of mhc class i and a third linker peptide; Method of production; pharmaceutical formulation that includes it; and its use
JP2019501882A5 (en)
PE20190477A1 (en) NEW T-LYMPHOCYTE AND IMMUNOTHERAPY RECEPTORS BASED ON THE USE OF THE SAME
BR112016027805A2 (en) human anti-papillomavirus t-cell receptors 16 e7
RU2017130985A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS
Silvin et al. Innate immune sensing of HIV infection
AR079114A1 (en) ANTI-ORAI1 ANTIGEN LINK PROTEINS AND USES OF THE SAME
PE20210376A1 (en) PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONIC ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER
BR112016015512A2 (en) chimeric factor viii proteins and their uses
PE20171336A1 (en) ANTIBODIES AGAINST TAU AND ITS USES
JP2015212284A5 (en)
Gao et al. Designing a soluble near full-length HIV-1 gp41 trimer
MX2023007282A (en) Ror1-specific variant antigen binding molecules.
PE20181897A1 (en) IMMUNOTHERAPY AGAINST MELANOMA AND OTHER TYPES OF CANCER
Contarino et al. Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1
PE20230343A1 (en) PEPTIDES THAT STIMULATE ANTI-TUMORAL IMMUNE RESPONSES
PE20210918A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DYSTROPHY